Core Viewpoint - UTime Limited is actively participating in international medical fairs and conferences to showcase its innovations in medical devices and solutions, aiming to enhance its global presence and partnerships in the healthcare industry [1][2]. Group 1: Upcoming Events - UTime will exhibit at MEDICA in Düsseldorf, Germany, focusing on medical monitoring devices and smart diagnostic tools, highlighting its innovations across the medical technology value chain [1]. - The company plans to attend several conferences in the United States, including the Cardiology Society Conference, Sleep Conference, and Hypertension Conference, providing a platform to present technological advancements and gain insights from industry experts [2]. Group 2: Commitment to Innovation - UTime's participation in these events reflects its commitment to influencing the global medical landscape and enhancing human health through technological innovation [2]. - The company aims to explore collaborative projects with international healthcare organizations and research institutes, particularly in telemedicine and artificial intelligence applications in healthcare, to accelerate the rollout of its products [3]. Group 3: Company Overview - UTime is dedicated to transforming health and wellness through innovative medical wearable technologies, leveraging research and strategic partnerships to provide effective solutions for disease prevention and health management globally [4].

Core Insights - UTime Limited is advancing its strategy in AI-driven health solutions, focusing on smart medical wearable products [1][2] - The company is collaborating with Dr. Ehud Baron to enhance its blood pressure measurement offerings and expand into hemodynamic and health mapping products [1] - UTime plans to launch additional products for monitoring key health indicators, including heart rate and sleep [2] Company Overview - UTime Limited, established in 2008, aims to provide cost-effective mobile devices globally, particularly for low-income individuals [3] - Since 2024, the company has been dedicated to transforming health and wellness through innovative medical wearable technologies [3] - UTime seeks to leverage research and strategic partnerships to offer effective solutions for disease prevention and health management [3]

Executive Compensation - The company reported an aggregate compensation of RMB 0.7 million (approximately $0.1 million) to executive officers for the fiscal year ended March 31, 2024[296]. - No cash compensation was paid to non-executive directors during the same fiscal year[296]. - The company has not granted any equity awards to directors or executive officers for the fiscal year ended March 31, 2024[296]. - The company has not set aside or accrued any amounts for pension or retirement benefits for directors and executive officers[296]. - The annual cash compensation for independent directors ranges from $100,000 to $120,000, with the possibility of equity payments[299]. - The cash compensation for newly appointed directors is approximately $435.60 (RMB 3,000) per year, paid quarterly[300]. - The company may terminate executive officers' employment without cause with 30 days' notice, providing severance payments not exceeding twelve months of base salary[110]. - The directors are not entitled to receive any remuneration upon termination of employment[302]. - The company has established a Compensation Committee to oversee executive compensation, ensuring compliance with independence standards[305]. Board Diversity - The board of directors consists of 5 members, with 1 female and 4 male directors[297]. - The company has a diverse board with no underrepresented individuals in the home country jurisdiction[297]. Financial Reporting and Asset Management - The company follows the allowance method for uncollectible accounts receivable, regularly assessing collectability based on historical experience and economic conditions[290]. - Inventory is stated at the lower of cost or net realizable value, with periodic assessments for impairment based on product life-cycle[292]. - The company reviews the carrying value of long-lived assets and recognizes impairment losses when anticipated cash flows are less than carrying value[292]. Share Issuance and Ownership - The company has registered an aggregate of 58,817,092 ordinary shares for issuance under the 2024 Performance Incentive Plan[308]. - As of July 29, 2024, there are 450,930,953 ordinary shares issued and outstanding, with directors and executive officers collectively owning 4,380,000 shares, representing 0.97%[305]. - The company has not issued any shares under the 2024 Performance Incentive Plan as of the date of the report[308]. Risk Management - The company faces foreign exchange risks due to international operations, particularly with revenue and expenses in U.S. dollars and Renminbi[310]. - The company has not been exposed to material risks due to changes in interest rates[394]. - Interest income is primarily generated from excess cash held in interest-bearing bank deposits[394]. - The company has not used any derivative financial instruments to manage interest rate risk exposure[394]. - Investments in fixed rate and floating rate interest-earning instruments carry a degree of interest rate risk[394]. - Fixed rate securities may have their fair market value adversely impacted by rising interest rates[394]. - Floating rate securities may produce less income than expected if interest rates fall[394]. - There are no applicable debt securities, warrants, rights, or other securities reported[395]. Audit and Compliance - The Audit Committee consists of three independent directors, with Na Cai serving as the chairman, ensuring compliance with Nasdaq listing rules[303].

NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- UTime Limited ("UTime" or the "Company") (NASDAQ:UTME), a mobile device manufacturing company committed to providing cost effective products and solutions to consumers globally and helping low-income individuals from established and emerging markets, today announced that on February 28, 2024, the Company received a written notification from the Nasdaq's Listing Qualifications Department, granting the Company another 180 calendar days extension, or until August 26 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________. OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR ...